1. |
|
|
2. |
|
|
3. |
- Schmitt, FA, et al.
(författare)
-
Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items
- 2010
-
Ingår i: American journal of Alzheimer's disease and other dementias. - : SAGE Publications. - 1938-2731 .- 1533-3175. ; 25:5, s. 407-413
-
Tidskriftsartikel (refereegranskat)abstract
- Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 to 12 mg/d rivastigmine capsules and 179 to placebo. Patients with PDD receiving rivastigmine improved versus placebo on items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language (P < .05), with standardized mean differences ranging from 0.04 to 0.30. Rivastigmine also showed significant effects versus placebo on all domains: memory, language, and praxis. The ADAS-cog is sensitive to broad cognitive changes in PDD. Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains.
|
|
4. |
|
|
5. |
|
|
6. |
|
|